Innovate Oncology Announces Exclusive Agreement With Prostagenics

Innovate Oncology, a company founded by Bioaccelerate Holdings, announced that it has entered into an exclusive agreement with Prostagenics, acquiring the rights to develop and commercialize Capridine-Beta for the treatment of prostate cancer. Capridine-Beta is a novel nitroacridine derivative that has shown specific activity against prostate cancer. It works by stimulating expression of p16, the tumor-suppressor gene and inhibits cyclic dependent kinases CDK-2, CDK-4 and CDK-6. Capridine-Beta also renders aggressive hormone-independent prostate cells hormone-sensitive.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19631520&full=1)